Gender differences in toxicokinetics, liver metabolism, and plasma esterase activity: Observations from a chronic (27-week) toxicity study of enalapril/diltiazem combinations in rats

Drug Metabolism and Disposition

Volumn 24, Issue 1, 1996, Pages 28-33

  Los, Layne E ^a   Welsh, Deborah A ^b   Herold, Eugene G ^b   Bagdon, Walter J ^b   Zacchei, Anthony G ^b  

^a AAI   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DEACETYLDILTIAZEM; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; ENALAPRIL; ESTERASE; FLUORIDE SODIUM; LIVER ENZYME; N NORDILTIAZEM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; LIVER METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; TOXICOKINETICS;

ANIMALS; ANTIHYPERTENSIVE AGENTS; DILTIAZEM; ENALAPRIL; ESTERASES; FEMALE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEX FACTORS;

ANIMALIA;

EID: 0030030115     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. E. H. Ulm, M. Hichens, H. J. Gomez, A. E. Till, E. Hand, T. C. Vassil, J. Biollaz, H. R. Brunner, and J. L. Schelling: Enalapril maleate and a lysine analogue (MK-521): disposition in man. Br. J. Clin. Pharmacol. 14, 357-362 (1982).
2. E H. Ulm: Enalapril maleate (MK-0421), a potent nonsulfhydryl angiotensin-converting enzyme inhibitor: absorption, disposition, and metabolism in man. Drug Metab. Rev. 14, 99-110 (1983).
3. J. H. Lin, I. W. Chen, E. H. Ulm, and D. E. Duggan: Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats. Drug Metab. Dispos. 16, 392-396 (1988).
4. D. J. Tocco, F. A. deLuna, A. E. W. Duncan, T. C. Vassil, and E. H. Ulm: The physiological disposition and metabolism of enalapril maleate in laboratory animals. Drug Metab. Dispos. 10, 15-19 (1982).
5. Y. H. Lee, M. H. Lee, and C. K. Shim: Pharmacokinetics of diltiazem and deacetyldiltiazem in rats. Int. J. Pharm. 76, 71-76 (1991).
6. S. Nakamura, T. Suzuki, Y. Sugawara, S. Usuki, Y. Ito, T. Kume, M. Yoshikawa, H. Endo, M. Ohashi, and S. Harigaya: Metabolite fate of diltiazem: distribution, excretion and protein binding in rat and dog. Arzneimittelforschung 37, 1244-52 (1987).
7. N. Yabana, T. Nagao, and M. Sato: Cardiovascular effects of the metabolites of diltiazem in dog. J Cardiovasc. Pharmacol. 7, 152-157 (1985).
8. K. Hattori, M. Igarashi, M. Itoh, H. Tomisawa, and M. Tateishi: Specific induction by glucocorticoids of steroid esterase in rat hepatic microsomes and its release into serum. Biochem. Pharmacol. 43, 1921-1927 (1992).
9. K. Hattori, M. Igarashi, M. Itoh, H. Tomisawa, N. Ozawa, and M. Tateishi: Purification and characterization of glucocordcoid-inducible steroid esterase in rat hepatic microsomes. Biochem. Pharmacol. 43, 1929-1937 (1992).
10. V. V. Sarveswar, R. Rambhau, and D. Rambhau: Chronopharmacokinetics of diltiazem. Drug Invest 6, 10-15 (1993).
11. G. P. Quinn, J. Axelrod, and B. B. Brodie. Species strain and sex differences in metabolism of hexobarbitone, aminopyrine, antipyrene and aniline. Biochem. Pharmacol. 1, 152-159 (1958).